SciELO - Scientific Electronic Library Online

 
vol.68 número1Prevalence of hearing loss and tinnitus in a group of adults with Human Immunodeficiency Virus índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • En proceso de indezaciónSimilares en Google

Compartir


South African Journal of Communication Disorders

versión On-line ISSN 2225-4765
versión impresa ISSN 0379-8046

Resumen

KHOZA-SHANGASE, Katijah  y  PRODROMOS, Marina. Impact of drug-resistant tuberculosis treatment on hearing function in South African adults: Bedaquiline versus kanamycin. S. Afr. J. Commun. Disord. [online]. 2021, vol.68, n.1, pp.1-8. ISSN 2225-4765.  http://dx.doi.org/10.4102/sajcd.v68i1.784.

BACKGROUND: Ototoxicity linked to medications used to treat tuberculosis (TB) remains a global challenge OBJECTIVES: The aim was to describe the audiological function in a group of adults with drug-resistant tuberculosis (DR-TB) on bedaquiline (G-BDQ) treatment attending a TB hospital in South Africa and compare this with patients on kanamycin (G-KCIN). METHODS: A quantitative paradigm was adopted within a non-experimental retrospective record review design. The sample consisted of 30 records of adults with DR-TB between the ages of 18 and 50 years, recruited from a Tropical Diseases Hospital in South Africa. Data were analysed through both descriptive and inferential statistical measures. RESULTS: Clear and statistically significant differences in the audiological function were found between the two groups. The group receiving G-KCIN presented with ototoxicity that was clearly demonstrated by sensorineural hearing loss of high-frequency worsening of thresholds in over 73% of the records, which was statistically (p < 0.05) and clinically significant, over the three testing sessions, demonstrating the cumulative effects of dosage. Increased evidence of tinnitus was also found in this group. The group receiving G-BDQ presented with neither statistically (p > 0.05) nor clinically significant changes in hearing thresholds across all frequencies over the same monitoring timeframe. Additionally, only one report (7%) of tinnitus was found in this group. CONCLUSION: The results indicating that bedaquiline does not cause hearing loss when compared with G-KCIN highlight the need for increased availability of bedaquiline for the treatment of DR-TB within the South African context, to preserve both the quantity and quality of life of those infected.

Palabras clave : bedaquiline; drug-resistant tuberculosis; hearing; kanamycin; monitoring; ototoxicity.

        · texto en Inglés     · Inglés ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons